Compass Therapeutics
Compass Therapeutics is dedicated to developing next-generation antibodies into transformative cancer therapies that improve patients' lives. They leverage their understanding of the tumor microenvironment to develop product candidates designed to optimize critical components for an effective anti-tumor response. Their approach involves proprietary antibody discovery engines, platforms like StitchMabs™ and common light chain technologies, enabling rapid identification of therapeutic leads with exceptional speed and diversity. The company targets the immune synapse with innovative therapies, bridging innate and adaptive immune systems, and has a diverse pipeline of monoclonal and multispecific candidates. They emphasize an unbiased, empirical approach to drug discovery, focusing on synergy and unexpected combinations, with a strong commitment to ethical research and community building.
Industries
Nr. of Employees
medium (51-250)
Compass Therapeutics
80 Guest Street, Suite 601, Boston MA 02135
Products
CTX-009
A bispecific antibody targeting DLL4 and VEGF-A, showing clinical benefit in advanced colorectal and gastric cancers.
CTX-471
A CD137 agonist in monotherapy for melanoma, aiming to initiate studies in the U.S. in H2 2024.
CTX-8371
A bispecific antibody targeting PD-1 and PD-L1, undergoing preclinical development for solid tumors.
StitchMabs™
A platform for creating bispecific antibodies by linking monoclonal antibodies into customized formats.
Common light chain-focused antibody discovery
A method for generating diverse antibody panels targeting over 40 immune system components.
Human display for antibody tuning
A mammalian display platform for optimizing monoclonal antibodies' specificity, affinity, and cross-reactivity.
CTX-009
A bispecific antibody targeting DLL4 and VEGF-A, showing clinical benefit in advanced colorectal and gastric cancers.
CTX-471
A CD137 agonist in monotherapy for melanoma, aiming to initiate studies in the U.S. in H2 2024.
CTX-8371
A bispecific antibody targeting PD-1 and PD-L1, undergoing preclinical development for solid tumors.
StitchMabs™
A platform for creating bispecific antibodies by linking monoclonal antibodies into customized formats.
Common light chain-focused antibody discovery
A method for generating diverse antibody panels targeting over 40 immune system components.
Human display for antibody tuning
A mammalian display platform for optimizing monoclonal antibodies' specificity, affinity, and cross-reactivity.
News & Updates
Latest news update about the company's participation in a major healthcare conference.
A scientific article or presentation related to the company's research on CTX-471.
A scientific article or presentation related to the company's research on CTX-471.
A publication about a clinical trial involving CTX-009.
A scientific article or presentation about the phase 1 study of CTX-471.
Latest news update about the company's participation in a major healthcare conference.
A scientific article or presentation related to the company's research on CTX-471.
A scientific article or presentation related to the company's research on CTX-471.
A publication about a clinical trial involving CTX-009.
A scientific article or presentation about the phase 1 study of CTX-471.